JP2007506768A5 - - Google Patents

Download PDF

Info

Publication number
JP2007506768A5
JP2007506768A5 JP2006528240A JP2006528240A JP2007506768A5 JP 2007506768 A5 JP2007506768 A5 JP 2007506768A5 JP 2006528240 A JP2006528240 A JP 2006528240A JP 2006528240 A JP2006528240 A JP 2006528240A JP 2007506768 A5 JP2007506768 A5 JP 2007506768A5
Authority
JP
Japan
Prior art keywords
composition
less
particles
composition according
diameter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006528240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007506768A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/031444 external-priority patent/WO2005030220A1/en
Publication of JP2007506768A publication Critical patent/JP2007506768A/ja
Publication of JP2007506768A5 publication Critical patent/JP2007506768A5/ja
Pending legal-status Critical Current

Links

JP2006528240A 2003-09-26 2004-09-24 肺疾患処置 Pending JP2007506768A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50646803P 2003-09-26 2003-09-26
US55159604P 2004-03-09 2004-03-09
PCT/US2004/031444 WO2005030220A1 (en) 2003-09-26 2004-09-24 Pulmonary disease treatment

Publications (2)

Publication Number Publication Date
JP2007506768A JP2007506768A (ja) 2007-03-22
JP2007506768A5 true JP2007506768A5 (enExample) 2007-10-11

Family

ID=34396317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006528240A Pending JP2007506768A (ja) 2003-09-26 2004-09-24 肺疾患処置

Country Status (6)

Country Link
US (3) US20050148563A1 (enExample)
EP (1) EP1667687A1 (enExample)
JP (1) JP2007506768A (enExample)
CA (1) CA2540005A1 (enExample)
MX (1) MXPA06003376A (enExample)
WO (1) WO2005030220A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148262A1 (en) * 2009-06-17 2010-12-23 Mark Rutenberg Treatment of acute pulmonary inflammation induced by cigarette smoking
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2668941A1 (en) * 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
EP0969816B1 (en) * 1997-03-20 2004-12-15 Schering Corporation Preparation of powder agglomerates
JP3676674B2 (ja) * 1997-10-09 2005-07-27 シェーリング コーポレイション 噴霧のためのモメタゾンフロエート懸濁液
SE9801368D0 (sv) * 1998-04-20 1998-04-20 Astra Ab New use
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB0009609D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic compositions
GB0123951D0 (en) * 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases

Similar Documents

Publication Publication Date Title
JP6099609B2 (ja) 肺炎症を低減するためのレボフロキサシンの吸入
ES2200837T3 (es) Combinaciones de formoterol y furoato de mometasona.
AU2001295760A1 (en) Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
JP2012503668A5 (enExample)
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
CN1314811A (zh) 治疗肺病的方法
CA2550841A1 (en) Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
JP2008505857A5 (enExample)
WO2009112274A3 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2020532531A5 (enExample)
Kilfeather et al. Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft MistTM Inhaler in patients with COPD
JP2007506768A5 (enExample)
HUE031442T2 (en) Aclidinium for use in improving the quality of sleep in respiratory patients.
KR20150011379A (ko) 옥시부티닌 투여를 위한 방법 및 조성물
JP2009534367A5 (enExample)
JP2008502699A5 (enExample)
JP2010523662A5 (enExample)
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
CN103168038A (zh) 用于治疗咳嗽的碳酸酯衍生物
JP2006508993A5 (enExample)
MXPA03007017A (es) Medicamentos.
Smith Fixed-combination inhalers for asthma and chronic obstructive pulmonary disease
CN115835862A (zh) 治疗阿尔茨海默病的组合及其应用
JP2017511307A5 (enExample)
Vogelberg et al. Dose-ranging study of tiotropium as treatment for moderate persistent asthma in adolescents